Wealthfront Advisers
BIO icon

Wealthfront Advisers’s Bio-Rad Laboratories Class A BIO Stock Holding History

Wealthfront Advisers’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,193
Closed -$413K – 874
2024
Q1 		$413K Sell
1,193
-130
-10% -$42.7K ﹤0.01% 757
2023
Q4 		$427K Buy
1,323
+610
+86% +$191K ﹤0.01% 744
2023
Q3 		$256K Buy
+713
New +$275K ﹤0.01% 784
2023
Q2 		– Sell
-585
Closed -$280K – 825
2023
Q1 		$280K Buy
585
+28
+5% +$13.1K ﹤0.01% 759
2022
Q4 		$234K Sell
557
-32
-5% -$12.9K ﹤0.01% 750
2022
Q3 		$246K Sell
589
-388
-40% -$193K ﹤0.01% 722
2022
Q2 		$484K Sell
977
-424
-30% -$221K ﹤0.01% 599
2022
Q1 		$789K Buy
1,401
+108
+8% +$65.1K ﹤0.01% 557
2021
Q4 		$977K Sell
1,293
-15
-1% -$11.2K ﹤0.01% 496
2021
Q3 		$975K Buy
1,308
+23
+2% +$17.2K ﹤0.01% 476
2021
Q2 		$828K Sell
1,285
-49
-4% -$29.8K ﹤0.01% 457
2021
Q1 		$762K Sell
1,334
-149
-10% -$88.2K ﹤0.01% 411
2020
Q4 		$865K Buy
1,483
+330
+29% +$188K 0.01% 377
2020
Q3 		$594K Buy
1,153
+646
+127% +$327K ﹤0.01% 397
2020
Q2 		$229K Buy
+507
New +$224K ﹤0.01% 482

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wealthfront Advisers's BIO Position: Q2 2024 in Review

Wealthfront Advisers sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 1,193 shares — an estimated $413K sold.

Wealthfront Advisers first reported a position in BIO in Q2 2020 and held it in 15 quarters. The position peaked at $977K in Q4 2021. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

  • Wealthfront Advisers reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
  • Wealthfront Advisers sold 1,193 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $413K.
  • Wealthfront Advisers first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 15 quarters.
  • Wealthfront Advisers's Bio-Rad Laboratories Class A position peaked at $977K in Q4 2021.
  • 440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Wealthfront Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.